Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Cell Biology

Background:

• Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are critical respiratory conditions marked by hypoxemia and inflammation.
• Valsartan, an angiotensin II type 1 receptor antagonist, has demonstrated anti-inflammatory and antioxidant properties.
• The therapeutic potential of valsartan in lipopolysaccharide (LPS)-induced ALI requires further investigation.

Purpose of the Study:

• To investigate the protective effects of valsartan against LPS-induced ALI.
• To elucidate the underlying mechanisms of valsartan's action in ALI.

Main Methods:

• Establishment of LPS-induced ALI models in BEAS-2B cells and mice.
• Administration of valsartan and assessment of pulmonary function, pathological lung injury, and inflammatory markers.
• Evaluation of oxidative stress, MUC5AC production, and key signaling pathways (MAPK, NF-κB) using molecular techniques.

Main Results:

• Valsartan improved cell viability, pulmonary function, and ameliorated lung injury in ALI models.
• It attenuated neutrophil recruitment, oxidative stress (increased SOD, decreased MDA/GSSG), and MUC5AC overproduction.
• Valsartan inhibited LPS-induced phosphorylation of NF-κB and MAPKs (P38, ERK, JNK).

Conclusions:

• Valsartan exhibits protective effects against LPS-induced ALI.
• Mechanisms involve the attenuation of oxidative stress, MUC5AC production, and inflammatory responses via MAPK and NF-κB pathways.